Core Viewpoint - A class action has been filed against Agenus Inc. for allegedly misleading investors about the effectiveness and prospects of its drug candidates, particularly botensilimab and balstilimab, during the specified class period [1][2]. Group 1: Company Overview - Agenus Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology products, including balstilimab, an anti-PD-1 antagonist, and botensilimab, a CTLA-4 blocking antibody [1]. - The company is currently conducting Phase 2 clinical trials for both drug candidates, targeting second line cervical cancer and pancreatic cancer/melanoma, respectively [1]. Group 2: Allegations and Legal Action - The class action alleges that Agenus failed to disclose that the combination therapy of botensilimab and balstilimab was less effective than represented, leading to overstated clinical results and regulatory prospects [2]. - Following a press release on July 18, 2024, regarding an FDA meeting, Agenus's stock price dropped by $10.43 per share, or 58.83%, closing at $7.30 per share, after the FDA advised against submission for Accelerated Approval due to concerns over survival benefits [3]. Group 3: Next Steps for Shareholders - Shareholders interested in participating in the class action must submit their application to serve as lead plaintiff by November 5, 2024 [4]. - Shareholders can choose to remain absent class members without participating in the case while still being eligible for recovery [4].

NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Agenus investors who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?pri ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Agenus Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class action pertains to securities purchased between January 23, 2023, and July 17, 2024, with a lead plaintiff deadline set for November 5, 2024 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [4] Group 2: Allegations Against Agenus - The lawsuit alleges that Agenus made false and misleading statements regarding the effectiveness of its combination therapy involving botensilimab and balstilimab [3] - It is claimed that the clinical results and regulatory prospects of these therapies were overstated, leading to materially false public statements [3] - The lawsuit asserts that investors suffered damages when the true details about the therapies were revealed [3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [2] - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [2] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [2]

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Agenus investors who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?pri ...

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN). Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=104517&from=3  CLASS PERIOD: January 23, 2023 to July ...

NEW YORK, Sept. 23, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=104025&from=4CLASS PERIOD: January 23, 2023 to July 17, 2024 ...

Core Viewpoint - A class action has been filed against Agenus Inc. for allegedly misleading investors regarding the effectiveness and prospects of its drug candidates, particularly botensilimab and balstilimab, during the specified class period [1][2]. Group 1: Company Overview - Agenus Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology products, including balstilimab, an anti-PD-1 antagonist, and botensilimab, a CTLA-4 blocking antibody [1]. - The company is currently conducting Phase 2 clinical trials for both drug candidates, targeting second line cervical cancer and pancreatic cancer/melanoma, respectively [1]. Group 2: Allegations and Legal Action - The allegations state that Agenus failed to disclose that the combination therapy of botensilimab and balstilimab was less effective than claimed, leading to overstated clinical results and regulatory prospects [2]. - Following a press release on July 18, 2024, regarding the FDA's feedback on the drug combination, Agenus's stock price dropped by $10.43 per share, or 58.83%, closing at $7.30 per share [3]. Group 3: Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must submit their applications by November 5, 2024, although participation is not required to be eligible for recovery [4].

NEW YORK, Sept. 20, 2024 /PRNewswire/ --, September 20, 2024 – Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Agenus investors who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/agenus-lawsuit-sub ...

Core Viewpoint - A class action securities lawsuit has been filed against Agenus Inc. for alleged securities fraud affecting investors between January 23, 2023, and July 17, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Agenus made false statements regarding the effectiveness of its immuno-oncology combination therapy involving botensilimab and balstilimab, which were overstated [2]. - The complaint alleges that the clinical results and regulatory prospects of botensilimab and balstilimab were misrepresented, leading to materially false and misleading public statements [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 5, 2024, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [2]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [2]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Agenus Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its immuno-oncology products, botensilimab and balstilimab, during the class period from January 23, 2023, to July 17, 2024 [1][2]. Group 1 - The class action alleges that the combination therapy of botensilimab and balstilimab was less effective than represented, leading to overstated clinical results and regulatory prospects [1]. - Shareholders who purchased shares during the specified class period are encouraged to register for potential lead plaintiff appointment, with a deadline set for November 5, 2024 [2]. - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements that inflated the company's stock value [3].